BRAIN Group company Analyticon Discovery extends its collaboration with clinical-stage company Pharvaris, focused on bringing oral bradykinin-B2-receptor antagonist small molecules to patients.
At EFIB 2021, representatives from business and politics finally met again in-person, where biotechnology as a driver of the bioeconomy and the hope for an early amendment of the European genetic engineering law was discussed.
BRAIN Biotech together with ImmunogenX optimizes a bioprocess for the production of a therapeutic protein
Scientists at BRAIN have demonstrated by a specially developed cell-based assay in the laboratory that bioactive substances from the BRAIN Bioarchive can activate skin cells. Industrial customers, e.g. from the cosmetics industry, can now use the test system to screen natural substances from the BRAIN substance library according to their specifications and thus find natural active ingredients for skin regeneration.
